Literature DB >> 11554141

[Surgical and adjuvant therapy of neuroendocrine tumors of the gastrointestinal tract and their metastases. A retrospective analysis of personal patient group].

S Schmidbauer1, R Ladurner, H Jückstock, A W Trupka, T Mussack, K K Hallfeldt.   

Abstract

INTRODUCTION: Carcinoid tumors are the most common neuroendocrine tumors of the gastrointestinal tract. Surgical treatment and prognosis depend on the location of the tumor.
METHOD: Between 01.01.1985 and 31.12.1999 25 patients with neuroendocrine tumors of the gastrointestinal tract or their metastases were treated in our institution. The records of these patients were reviewed retrospectively. Patients still alive were reexamined clinically. RESULTS AND
CONCLUSIONS: The most frequent primary sites were the ileum and jejunum (36%), appendix (36%), stomach (12%), pancreas (8%), colon (4%) and bronchus with hepatic metastasis (4%). A malignant carcinoid syndrome was present in 8 patients. In patients with neuroendocrine tumors, curative, radical tumor removal should be attempted. Some patients with advanced disease needed some surgery for tumor debulking and resection of metastases. In non-resectable liver metastases hepatic arterial chemotherapy and chemoembolization after implantation of port catheters seem to be very beneficial therapeutic options. A fixed part of the therapeutic regime in progressive disease is adjuvant chemotherapy with 5-fluorouracil and streptozotocin and symptomatic therapy with octreotide.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11554141     DOI: 10.1007/s001040170094

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  3 in total

1.  Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?

Authors:  H Amthauer; J Ruf; M Böhmig; E Lopez-Hänninen; T Rohlfing; K-D Wernecke; U Plöckinger; M Gutberlet; A-J Lemke; T Steinmüller; B Wiedenmann; R Felix
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-03       Impact factor: 9.236

2.  Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.

Authors:  James R Barrett; Victoria Rendell; Courtney Pokrzywa; Alexandra G Lopez-Aguiar; John Cannon; George A Poultsides; Flavio Rocha; Angelena Crown; Eliza Beal; Timothy Michael Pawlik; Ryan Fields; Roheena Z Panni; Paula Smith; Kamran Idrees; Clifford Cho; Megan Beems; Shishir Maithel; Sharon Weber; Daniel Erik Abbott
Journal:  J Surg Oncol       Date:  2020-03-09       Impact factor: 3.454

Review 3.  [Combined therapies including interventional radiology].

Authors:  S Clasen; P L Pereira
Journal:  Radiologe       Date:  2007-12       Impact factor: 0.803

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.